XTX101
xilio therapeutics
['xilio']
recently, we shared preliminary phase 1 data for xtx101, an investigational, tumor-activated, fc-enhanced anti-ctla-4. read our press release: #cancerresearch #asco23 #onctwitter
We're advancing next-generation cancer immunotherapies by unleashing the power of the immune system selectively at the site of the tumor